According to the Attention Deficit Disorder (ADD) Information Center, 3% to 10% of the U.S. population is affected with ADD and its many forms (ADHD/LD). As a result, an estimated 20 million children may be placed on activity-modifying drugs like Methlyphenidate before the year 2000.
Attention deficit disorder drugs have been suspected of retarding growth of attention deficit individuals, which ironically is the last thing you would want to do with individuals who have been neurally limited! Amphetamines, antidepressants or anticonvulsants normally prescribed for ADD have been shown to detrimentally diminish cognitive activity and exhibit harmful side effects, such as nervousness, insomnia and anorexia.
Attention Deficit is big business in the U.S. where therapies for ADD/ADHD have reached $2 billion. In Europe, Attention Deficit diagnosis is only one-tenth as common as it is in the U.S., and in Japan, the disorder has barely been noted. Consumption of the mood-altering drug Methlyphenidate in the U.S. versus the rest of the world has become so disparate that the Vienna-based International Narcotics Control Board has asked American authorities to monitor it to be certain it is being properly prescribed.